CKDB001 Probiotic Composition for NAFLD Steatosis and Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional therapies for non-alcoholic fatty liver disease (NAFLD) are often ineffective due to poor compliance, lack of efficacy, or changes in diet and lifestyle, and there is a need for a more effective probiotic-based solution to manage NAFLD, non-alcoholic steatohepatitis, and related conditions.
Innovation Solution
A Lactobacillus delbrueckii subsp. lactis CKDB001 strain, combined with Bifidobacterium strains, is used to develop a composition that reduces steatosis and inflammation in animal models of high-fat diet-induced NAFLD, administered through various food and pharmaceutical formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for NAFLD, then treatment coverage is broad, but efficacy is poor and compliance is low
Solution Approach 1:
The patent changes the therapeutic parameter from conventional pharmacological agents to probiotic bacteria (Lactobacillus delbrueckii subsp. lactis CKDB001), fundamentally altering the mode of action from chemical intervention to biological modulation. This parameter change addresses both efficacy and compliance by providing a natural, well-tolerated therapeutic agent that modifies gut microbiota composition to treat NAFLD.
Solution Approach 2:
The probiotic strain acts as an intermediary between the gut microbiota and liver metabolism. By modulating the gut-liver axis through probiotic administration, the patent creates a indirect therapeutic pathway that improves liver function without direct hepatic intervention, thereby enhancing both efficacy and patient compliance.
2Reliability
If probiotic regulation is implemented, then therapeutic effectiveness improves, but mechanism complexity increases
Solution Approach 1:
The patent extracts and isolates a specific probiotic strain (Lactobacillus delbrueckii subsp. lactis CKDB001) with demonstrated efficacy against NAFLD from the complex probiotic ecosystem. By selecting and standardizing a single effective strain, the patent simplifies the therapeutic mechanism while maintaining therapeutic effectiveness, making it easier to manufacture and administer.
3Stability of the object's composition
If a specific probiotic strain is isolated and standardized, then product consistency improves, but development time and cost increase
Solution Approach 1:
The patent performs preliminary screening and selection of the Lactobacillus delbrueckii subsp. lactis CKDB001 strain before full-scale development, establishing its efficacy and safety in advance. This preliminary action includes in vitro and in vivo validation studies that confirm the strain's ability to modulate gut microbiota and improve liver parameters, thereby reducing later development risks and time.
Data Source
AI summary
The present invention relates to a Lactobacillus lactis CKDB001 strain, and a composition for the prevention or treatment of non-alcoholic fatty liver comprising same. When the composition of the present invention is ingested, the composition has the effect of ameliorating high-fat diet-induced fatty cirrhosis and inflammations caused thereby, and thus the composition of the present invention can be effectively used as a preparation for ameliorating or treating non-alcoholic fatty cirrhosis and steatohepatitis.